Merck, a leading science and technology company, announced its participation in a collaboration with the Vaccine Formulation Institute and the European Vaccine Initiative. The effort will provide vaccine process development training courses within TRANSVAC2, a collaborative infrastructure project under Horizon 2020.
See full press release: https://www.merckgroup.com/en/news/transvac2-program-joining-20-05-2019.html
TRANSVAC2 has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement N° 730964.
This communication reflects only the author's view and the European Commission is not responsible for any use that may be made of the information it contains.